RecallRadar

FDA Drug recall D-0590-2021

VIMPAT (lacosamide) Tablets, 200mg, 60-count bottle, Rx Only, Manufactured for: UCB, Inc

On 2021-06-02 the FDA classified a Class II recall of VIMPAT (lacosamide) Tablets, 200mg, 60-count bottle, Rx Only, Manufactured for: UCB, Inc by Cardinal Health, citing CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0590-2021
ClassificationClass II
Statusterminated
Initiated2021-03-15
Published2021-06-02
Last updated2026-09-13 11:52 UTC
CompanyCardinal Health
DistributionFL, GA, SC

Product

VIMPAT (lacosamide) Tablets, 200mg, 60-count bottle, Rx Only, Manufactured for: UCB, Inc. Smyrna, GA 30080, NDC 0131-2480-35

Reason

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Identifiers

ndc0131-2477-35
ndc0131-2477-60
ndc0131-2477-99
ndc0131-2478-35
ndc0131-2478-60
ndc0131-2478-99
ndc0131-2479-35
ndc0131-2479-60
ndc0131-2479-99
ndc0131-2480-35
ndc0131-2480-60
ndc0131-2480-99
ndc0131-1810-67
ndc0131-5410-70
ndc0131-5410-71
ndc0131-5410-72
code_info912064

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0590-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.